1. Strengthening the credibility of clinical research. Lancet. 2010; 375: 1225.

2. Nissen S. Slides presented at the FDA advisory meeting about rosiglitazone. 2010 July 13.

3. Cohen D. Rosiglitazone: what went wrong? BMJ. 2010; 341: 530–4.

4. Harris G. Diabetes drug maker hid test data. New York Times. 2010 July 13.

5. Gøtzsche P.C. Why we need easy access to all data from all clinical trials and how to accomplish it. Trials. 2011; 12: 249.

6. Khan H., Thomas P. Drug giant AstraZeneca to pay $520 million to settle fraud case. ABC News. 2010 April 27.

7. Bass A. Side Effects – a prosecutor, a whistleblower, and a bestselling antidepressant on trial. Chapel Hill: Algonquin Books; 2008.

8. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356: 2457–71.

9. Nissen S.E. Setting the RECORD straight. JAMA. 2010; 303: 1194–5.

10. Mitka M. Critics press FDA to act on evidence of rosiglitazone’s cardiac safety issues. JAMA. 2010; 303: 2341–2.

11. Moynihan R. Rosiglitazone, marketing, and medical science. BMJ. 2010; 340: c1848.

12. Home P.D., Pocock S.J., Beck-Nielsen H., et al. Rosiglitazone evaluated for cardiovascular outcomes an interim analysis. N Engl J Med. 2007; 357: 28–38.

13. Home P.D., Pocock S.J., Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009, 373: 2125–35.

14. Psaty B.M., Prentice R.L. Minimizing bias in randomized trials: the importance of blinding. JAMA. 2010; 304: 793–4.

15. Psaty B.M., Furberg C.D. The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med. 2007; 357: 67–9.

16. Graham D., Gelperin K. More on advisory committee decision. BMJ. 2010; 341: 519.

17. Mello M.M., Goodman S.N., Faden R.R. Ethical considerations in studying drug safety – the Institute of Medicine report. N Engl J Med. 2012; 367: 959–64.

18. Cohen D. FDA puts rosiglitazone post-marketing trial on hold. BMJ. 2010; 341: c4017.

19. Tanne J.H. GSK is accused of trying to suppress editorial on rosiglitazone. BMJ. 2010; 340: c2654.

20. Slaoui M. The rise and fall of rosiglitazone: reply. Eur Heart J. 2010; 31: 1282–4.

21. FDA Drug Safety Communication. Avandia (Rosiglitazone) Labels now Contain Updated Information about Cardiovascular Risks and Use in Certain Patients. 2011 Mar 3.

22. Wang A.T., McCoy C.P., Murad M.H., et al. Association between industry affi liation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. BMJ. 2010; 340: c1344.

23. Lehman R., Yudkin J.S., Krumholz H.M. Licensing drugs for diabetes. BMJ. 2010; 341: 513–14.

24. Solomon D.H., Winkelmayer W.C. Cardiovascular risk and the thiazolidinediones: déjà vu all over again? JAMA. 2007; 298: 1216–18.

25. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366: 1279–89.

26. Charbonnel B., Dormandy J., Erdmann E., et al. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care. 2004; 27: 1647–53.

27. PROactive Study Executive Committee and Data and Safety Monitoring Committee. PROactive study. Lancet. 2006; 367: 982.

28. Gøtzsche P.C., Hróbjartsson A., Johansen H.K., et al. Constraints on publication rights in industryinitiated clinical trials. JAMA. 2006; 295: 1645–6.

29. Chan A.-W., Hróbjartsson A., Haahr M.T., et al. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA. 2004; 291: 2457–65.

30. Chan A.-W., Hróbjartsson A., Jørgensen K.J., et al. Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols. BMJ. 2008; 337: a2299.

31. Jack A. European drugs watchdog to step up scrutiny. Financial Times. 2012 March 6.

32. Hillaire-Buys D., Faillie J.L., Montastruc J.L. Pioglitazone and bladder cancer. Lancet. 2011; 378: 1543–4.

33. European Medicines Agency. Assessment report, Pioglitazone ratio. EMA/391408/2012. 2012 May 24.

34. Ray W.A., Stein C.M. Reform of drug regulation – beyond an independent drug-safety board. N Engl J Med. 2006; 354: 194–201.

35. Hillaire-Buys D., Faillie J.L. Pioglitazone and the risk of bladder cancer. BMJ. 2012; 344: e3500.

36. FDA Drug Safety Communication. Update to Ongoing Safety Review of Actos (pioglitazone) and Increased Risk of Bladder Cancer. 2011 June 6.

37. Kassirer J.P. On the Take: how medicine’s complicity with big business can endanger your health. Oxford: Oxford University Press; 2005.

38. Avorn J. Powerful Medicines: the benefi ts, risks, and costs of prescription drugs. New York: Vintage Books; 2005.

39. Brody H. Hooked: ethics, the medical profession, and the pharmaceutical industry. Lanham: Rowman & Littlefi eld; 2008.

40. Nissen S.E., Wolski K., Topol E.J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005; 294: 2581–6.

41. Brophy J.M. Selling safety – lessons from muraglitazar. JAMA. 2005; 294: 2633–5.

42. Abramson J. Overdo$ed America. New York: HarperCollins; 2004.

43. Saenz A., Fernandez-Esteban I., Mataix A., et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005; 3: CD002966.

44. Wikipedia. Metformin. Available online at: http://en.wikipedia.org/wiki/Metformin (accessed 12 October 2012).

45. Spranger J., Gundert-Remy U., Stammschulte T. GLP-1-based therapies: the dilemma of uncertainty. Gastroenterology. 2011; 141: 20–3.

46. Elashoff M., Matveyenko A.V., Gier B., et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011; 141: 150–6.

47. Gøtzsche P.C., Mæhlen J., Zahl P.H. What is publication? Lancet. 2006; 368: 1854–6.

48. Public citizen to FDA: pull diabetes drug Victoza from market immediately. Public Citizen. 2012 April 19.

49. Lindeberg M. [Novo Nordisk has sent warnings about the cancer risk with its diabetes drug Victoza to US physicians]. Berlingske. 2011 June 14.

50. US Food and Drug Administration. FDA Approves New Treatment for Type 2 Diabetes. 2010 Jan 25.

51. Maxmen A. Debate on diabetes drugs gathers pace: petition unveils unnerving reports on potential carcinogenicity of GLP-1 mimics. Nature. 2012 April 30.